BidaskClub upgraded shares of BioTelemetry (NASDAQ:BEAT) from a sell rating to a hold rating in a research note released on Saturday, BidAskClub reports.

A number of other equities analysts have also recently issued reports on BEAT. Zacks Investment Research cut BioTelemetry from a hold rating to a sell rating in a report on Monday, August 3rd. Robert W. Baird assumed coverage on BioTelemetry in a report on Tuesday, September 1st. They set a neutral rating and a $43.00 target price on the stock. Needham & Company LLC assumed coverage on BioTelemetry in a report on Friday, September 11th. They set a buy rating and a $52.00 target price on the stock. Finally, SunTrust Banks restated a buy rating and set a $58.00 target price on shares of BioTelemetry in a report on Wednesday, July 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. BioTelemetry has a consensus rating of Hold and a consensus price target of $58.57.

BioTelemetry stock opened at $40.71 on Friday. The business’s 50-day simple moving average is $40.91 and its 200 day simple moving average is $42.29. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 78.29, a P/E/G ratio of 2.44 and a beta of 1.27. BioTelemetry has a 12-month low of $27.35 and a 12-month high of $55.85. The company has a quick ratio of 2.42, a current ratio of 2.52 and a debt-to-equity ratio of 0.41.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Thursday, July 30th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.19. The business had revenue of $99.11 million for the quarter, compared to analysts’ expectations of $85.93 million. BioTelemetry had a return on equity of 17.68% and a net margin of 4.42%. As a group, sell-side analysts expect that BioTelemetry will post 1.67 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of BioTelemetry during the second quarter worth about $37,000. Mutual of America Capital Management LLC raised its position in BioTelemetry by 21.8% in the 1st quarter. Mutual of America Capital Management LLC now owns 1,477 shares of the medical research company’s stock valued at $57,000 after buying an additional 264 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in BioTelemetry in the 2nd quarter valued at approximately $75,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in BioTelemetry by 48.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,938 shares of the medical research company’s stock valued at $113,000 after buying an additional 954 shares during the last quarter. Finally, Emerald Advisers LLC acquired a new stake in BioTelemetry in the 2nd quarter valued at approximately $185,000. 92.82% of the stock is currently owned by institutional investors.

About BioTelemetry

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Read More: Leveraged Buyout (LBO) Explained

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.